Medical Innovation Exchange

Iovance sinks 50% as pivotal cell therapy data disappoint investors, but approval plan pushes ahead anyway


Leave a Comment

Your email address will not be published.

Leave the field below empty!

This site uses Akismet to reduce spam. Learn how your comment data is processed.